View Financial HealthAccent Microcell 配当と自社株買い配当金 基準チェック /16Accent Microcell配当を支払う会社であり、現在の利回りは0.22%で、収益によって十分にカバーされています。主要情報0.2%配当利回り-4.1%バイバック利回り総株主利回り-3.9%将来の配当利回りn/a配当成長25.9%次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向6%最近の配当と自社株買いの更新お知らせ • Aug 23Accent Microcell Limited announces Annual dividend, payable on October 25, 2025Accent Microcell Limited announced Annual dividend of INR 1.0000 per share payable on October 25, 2025, ex-date on September 16, 2025 and record date on September 16, 2025.お知らせ • Sep 09Accent Microcell Limited Declares Final Dividend for the Financial Year Ended March 31, 2024Accent Microcell Limited declared a final Dividend of INR 01/- per fully paid-up equity share of INR 10/- each for the Financial Year Ended March 31, 2024.お知らせ • May 18Accent Microcell Limited Recommends Dividend for the Financial Year Ended 31 March, 2024Accent Microcell Limited announced that at its Board of Directors meeting held on May 17, 2024, recommended a final dividend at the rate of 10% on the Equity share capital of the company i.e. INR 1/- per equity share of INR 10/- each for the financial year ended 31 March, 2024, subject to the approval of shareholders at the Annual General Meeting of the Company.すべての更新を表示Recent updates分析記事 • May 20Accent Microcell's (NSE:ACCENTMIC) Profits Appear To Have Quality IssuesThe stock price didn't jump after Accent Microcell Limited ( NSE:ACCENTMIC ) posted decent earnings last week. We did...分析記事 • May 19With EPS Growth And More, Accent Microcell (NSE:ACCENTMIC) Makes An Interesting CaseThe excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Reported Earnings • May 13Full year 2026 earnings released: EPS: ₹18.65 (vs ₹15.71 in FY 2025)Full year 2026 results: EPS: ₹18.65 (up from ₹15.71 in FY 2025). Revenue: ₹3.56b (up 34% from FY 2025). Net income: ₹438.6m (up 33% from FY 2025). Profit margin: 12% (in line with FY 2025).お知らせ • May 08Accent Microcell Limited to Report Second Half, 2026 Results on May 12, 2026Accent Microcell Limited announced that they will report second half, 2026 results on May 12, 2026New Risk • May 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (58% accrual ratio). Minor Risks Latest financial reports are more than 6 months old (reported September 2025 fiscal period end). Market cap is less than US$100m (₹8.95b market cap, or US$94.4m).Valuation Update With 7 Day Price Move • Apr 06Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹409, the stock trades at a trailing P/E ratio of 24.8x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 121% over the past year.New Risk • Dec 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (58% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (7.1% average weekly change). Market cap is less than US$100m (₹7.22b market cap, or US$80.3m).Board Change • Nov 10Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Non-Executive Independent Director Chintan Bhatt was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.分析記事 • Sep 06Accent Microcell's (NSE:ACCENTMIC) Solid Earnings May Rest On Weak FoundationsAccent Microcell Limited's ( NSE:ACCENTMIC ) robust recent earnings didn't do much to move the stock. We think this is...お知らせ • Aug 23Accent Microcell Limited announces Annual dividend, payable on October 25, 2025Accent Microcell Limited announced Annual dividend of INR 1.0000 per share payable on October 25, 2025, ex-date on September 16, 2025 and record date on September 16, 2025.お知らせ • Aug 22Accent Microcell Limited, Annual General Meeting, Sep 25, 2025Accent Microcell Limited, Annual General Meeting, Sep 25, 2025, at 11:00 Indian Standard Time.New Risk • Jul 31New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 7.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (7.8% average weekly change). High level of non-cash earnings (36% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Market cap is less than US$100m (₹5.93b market cap, or US$67.7m).Valuation Update With 7 Day Price Move • Jul 31Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹316, the stock trades at a trailing P/E ratio of 20.1x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Total returns to shareholders of 17% over the past year.分析記事 • Jul 19Market Might Still Lack Some Conviction On Accent Microcell Limited (NSE:ACCENTMIC) Even After 25% Share Price BoostDespite an already strong run, Accent Microcell Limited ( NSE:ACCENTMIC ) shares have been powering on, with a gain of...Valuation Update With 7 Day Price Move • Jun 30Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹266, the stock trades at a trailing P/E ratio of 16.9x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Negligible returns to shareholders over past year.New Risk • Jun 08New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (38% accrual ratio). Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Paying a dividend despite having no free cash flows. Market cap is less than US$100m (₹4.84b market cap, or US$56.4m).Valuation Update With 7 Day Price Move • May 14Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹239, the stock trades at a trailing P/E ratio of 15.5x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total loss to shareholders of 23% over the past year.New Risk • Dec 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (38% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.1% average weekly change). Market cap is less than US$100m (₹6.20b market cap, or US$72.9m).分析記事 • Oct 25Investors Shouldn't Be Too Comfortable With Accent Microcell's (NSE:ACCENTMIC) EarningsLast week's profit announcement from Accent Microcell Limited ( NSE:ACCENTMIC ) was underwhelming for investors...Reported Earnings • Oct 20First half 2025 earnings released: EPS: ₹7.83 (vs ₹8.54 in 1H 2024)First half 2025 results: EPS: ₹7.83. Revenue: ₹1.26b (down 7.5% from 1H 2024). Net income: ₹164.7m (up 2.5% from 1H 2024). Profit margin: 13% (up from 12% in 1H 2024). The increase in margin was driven by lower expenses.お知らせ • Sep 09Accent Microcell Limited Declares Final Dividend for the Financial Year Ended March 31, 2024Accent Microcell Limited declared a final Dividend of INR 01/- per fully paid-up equity share of INR 10/- each for the Financial Year Ended March 31, 2024.お知らせ • Aug 05Accent Microcell Limited, Annual General Meeting, Sep 09, 2024Accent Microcell Limited, Annual General Meeting, Sep 09, 2024, at 11:30 Indian Standard Time.New Risk • May 19New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 38% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (38% accrual ratio). Minor Risk Market cap is less than US$100m (₹6.90b market cap, or US$82.9m).Reported Earnings • May 19Full year 2024 earnings released: EPS: ₹18.67 (vs ₹10.06 in FY 2023)Full year 2024 results: EPS: ₹18.67 (up from ₹10.06 in FY 2023). Revenue: ₹2.49b (up 22% from FY 2023). Net income: ₹301.7m (up 132% from FY 2023). Profit margin: 12% (up from 6.4% in FY 2023). The increase in margin was driven by higher revenue.お知らせ • May 18Accent Microcell Limited Recommends Dividend for the Financial Year Ended 31 March, 2024Accent Microcell Limited announced that at its Board of Directors meeting held on May 17, 2024, recommended a final dividend at the rate of 10% on the Equity share capital of the company i.e. INR 1/- per equity share of INR 10/- each for the financial year ended 31 March, 2024, subject to the approval of shareholders at the Annual General Meeting of the Company.Valuation Update With 7 Day Price Move • May 14Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹305, the stock trades at a trailing P/E ratio of 49.3x. Average trailing P/E is 34x in the Pharmaceuticals industry in India.Valuation Update With 7 Day Price Move • Apr 03Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹269, the stock trades at a trailing P/E ratio of 43.4x. Average trailing P/E is 33x in the Pharmaceuticals industry in India.Recent Insider Transactions • Mar 19CFO, MD & Director recently bought ₹21m worth of stockOn the 14th of March, Ghanshyam Patel bought around 91k shares on-market at roughly ₹231 per share. This transaction amounted to 3.3% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth ₹36m. Ghanshyam has been a buyer over the last 12 months, purchasing a net total of ₹57m worth in shares.Recent Insider Transactions • Jan 20CFO, MD & Director recently bought ₹36m worth of stockOn the 16th of January, Ghanshyam Patel bought around 120k shares on-market at roughly ₹301 per share. This transaction increased Ghanshyam's direct individual holding by 1x at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Ghanshyam's only on-market trade for the last 12 months.Board Change • Dec 15Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Non-Executive Independent Director Chintan Bhatt was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.決済の安定と成長配当データの取得安定した配当: 配当金の支払いは安定していますが、 ACCENTMICが配当金を支払っている期間は 10 年未満です。増加する配当: ACCENTMICは2年間のみ配当金を支払っており、それ以降支払額は増加していません。配当利回り対市場Accent Microcell 配当利回り対市場ACCENTMIC 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (ACCENTMIC)0.2%市場下位25% (IN)0.3%市場トップ25% (IN)1.5%業界平均 (Pharmaceuticals)0.7%アナリスト予想 (ACCENTMIC) (最長3年)n/a注目すべき配当: ACCENTMICの配当金 ( 0.22% ) はIndian市場の配当金支払者の下位 25% ( 0.3% ) と比べると目立ったものではありません。高配当: ACCENTMICの配当金 ( 0.22% ) はIndian市場の配当金支払者の上位 25% ( 1.5% ) と比較すると低いです。株主への利益配当収益カバレッジ: ACCENTMIC の配当性向 (6.4%) は低いため、配当金の支払いは利益によって十分にカバーされます。株主配当金キャッシュフローカバレッジ: ACCENTMICは配当金を支払っていますが、同社にはフリーキャッシュフローがありません。高配当企業の発掘7D1Y7D1Y7D1YIN 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/11 20:04終値2026/06/11 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Accent Microcell Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Aug 23Accent Microcell Limited announces Annual dividend, payable on October 25, 2025Accent Microcell Limited announced Annual dividend of INR 1.0000 per share payable on October 25, 2025, ex-date on September 16, 2025 and record date on September 16, 2025.
お知らせ • Sep 09Accent Microcell Limited Declares Final Dividend for the Financial Year Ended March 31, 2024Accent Microcell Limited declared a final Dividend of INR 01/- per fully paid-up equity share of INR 10/- each for the Financial Year Ended March 31, 2024.
お知らせ • May 18Accent Microcell Limited Recommends Dividend for the Financial Year Ended 31 March, 2024Accent Microcell Limited announced that at its Board of Directors meeting held on May 17, 2024, recommended a final dividend at the rate of 10% on the Equity share capital of the company i.e. INR 1/- per equity share of INR 10/- each for the financial year ended 31 March, 2024, subject to the approval of shareholders at the Annual General Meeting of the Company.
分析記事 • May 20Accent Microcell's (NSE:ACCENTMIC) Profits Appear To Have Quality IssuesThe stock price didn't jump after Accent Microcell Limited ( NSE:ACCENTMIC ) posted decent earnings last week. We did...
分析記事 • May 19With EPS Growth And More, Accent Microcell (NSE:ACCENTMIC) Makes An Interesting CaseThe excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
Reported Earnings • May 13Full year 2026 earnings released: EPS: ₹18.65 (vs ₹15.71 in FY 2025)Full year 2026 results: EPS: ₹18.65 (up from ₹15.71 in FY 2025). Revenue: ₹3.56b (up 34% from FY 2025). Net income: ₹438.6m (up 33% from FY 2025). Profit margin: 12% (in line with FY 2025).
お知らせ • May 08Accent Microcell Limited to Report Second Half, 2026 Results on May 12, 2026Accent Microcell Limited announced that they will report second half, 2026 results on May 12, 2026
New Risk • May 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (58% accrual ratio). Minor Risks Latest financial reports are more than 6 months old (reported September 2025 fiscal period end). Market cap is less than US$100m (₹8.95b market cap, or US$94.4m).
Valuation Update With 7 Day Price Move • Apr 06Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹409, the stock trades at a trailing P/E ratio of 24.8x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 121% over the past year.
New Risk • Dec 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (58% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (7.1% average weekly change). Market cap is less than US$100m (₹7.22b market cap, or US$80.3m).
Board Change • Nov 10Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Non-Executive Independent Director Chintan Bhatt was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
分析記事 • Sep 06Accent Microcell's (NSE:ACCENTMIC) Solid Earnings May Rest On Weak FoundationsAccent Microcell Limited's ( NSE:ACCENTMIC ) robust recent earnings didn't do much to move the stock. We think this is...
お知らせ • Aug 23Accent Microcell Limited announces Annual dividend, payable on October 25, 2025Accent Microcell Limited announced Annual dividend of INR 1.0000 per share payable on October 25, 2025, ex-date on September 16, 2025 and record date on September 16, 2025.
お知らせ • Aug 22Accent Microcell Limited, Annual General Meeting, Sep 25, 2025Accent Microcell Limited, Annual General Meeting, Sep 25, 2025, at 11:00 Indian Standard Time.
New Risk • Jul 31New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 7.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (7.8% average weekly change). High level of non-cash earnings (36% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Market cap is less than US$100m (₹5.93b market cap, or US$67.7m).
Valuation Update With 7 Day Price Move • Jul 31Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹316, the stock trades at a trailing P/E ratio of 20.1x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Total returns to shareholders of 17% over the past year.
分析記事 • Jul 19Market Might Still Lack Some Conviction On Accent Microcell Limited (NSE:ACCENTMIC) Even After 25% Share Price BoostDespite an already strong run, Accent Microcell Limited ( NSE:ACCENTMIC ) shares have been powering on, with a gain of...
Valuation Update With 7 Day Price Move • Jun 30Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹266, the stock trades at a trailing P/E ratio of 16.9x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Negligible returns to shareholders over past year.
New Risk • Jun 08New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (38% accrual ratio). Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Paying a dividend despite having no free cash flows. Market cap is less than US$100m (₹4.84b market cap, or US$56.4m).
Valuation Update With 7 Day Price Move • May 14Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹239, the stock trades at a trailing P/E ratio of 15.5x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total loss to shareholders of 23% over the past year.
New Risk • Dec 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (38% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.1% average weekly change). Market cap is less than US$100m (₹6.20b market cap, or US$72.9m).
分析記事 • Oct 25Investors Shouldn't Be Too Comfortable With Accent Microcell's (NSE:ACCENTMIC) EarningsLast week's profit announcement from Accent Microcell Limited ( NSE:ACCENTMIC ) was underwhelming for investors...
Reported Earnings • Oct 20First half 2025 earnings released: EPS: ₹7.83 (vs ₹8.54 in 1H 2024)First half 2025 results: EPS: ₹7.83. Revenue: ₹1.26b (down 7.5% from 1H 2024). Net income: ₹164.7m (up 2.5% from 1H 2024). Profit margin: 13% (up from 12% in 1H 2024). The increase in margin was driven by lower expenses.
お知らせ • Sep 09Accent Microcell Limited Declares Final Dividend for the Financial Year Ended March 31, 2024Accent Microcell Limited declared a final Dividend of INR 01/- per fully paid-up equity share of INR 10/- each for the Financial Year Ended March 31, 2024.
お知らせ • Aug 05Accent Microcell Limited, Annual General Meeting, Sep 09, 2024Accent Microcell Limited, Annual General Meeting, Sep 09, 2024, at 11:30 Indian Standard Time.
New Risk • May 19New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 38% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (38% accrual ratio). Minor Risk Market cap is less than US$100m (₹6.90b market cap, or US$82.9m).
Reported Earnings • May 19Full year 2024 earnings released: EPS: ₹18.67 (vs ₹10.06 in FY 2023)Full year 2024 results: EPS: ₹18.67 (up from ₹10.06 in FY 2023). Revenue: ₹2.49b (up 22% from FY 2023). Net income: ₹301.7m (up 132% from FY 2023). Profit margin: 12% (up from 6.4% in FY 2023). The increase in margin was driven by higher revenue.
お知らせ • May 18Accent Microcell Limited Recommends Dividend for the Financial Year Ended 31 March, 2024Accent Microcell Limited announced that at its Board of Directors meeting held on May 17, 2024, recommended a final dividend at the rate of 10% on the Equity share capital of the company i.e. INR 1/- per equity share of INR 10/- each for the financial year ended 31 March, 2024, subject to the approval of shareholders at the Annual General Meeting of the Company.
Valuation Update With 7 Day Price Move • May 14Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹305, the stock trades at a trailing P/E ratio of 49.3x. Average trailing P/E is 34x in the Pharmaceuticals industry in India.
Valuation Update With 7 Day Price Move • Apr 03Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹269, the stock trades at a trailing P/E ratio of 43.4x. Average trailing P/E is 33x in the Pharmaceuticals industry in India.
Recent Insider Transactions • Mar 19CFO, MD & Director recently bought ₹21m worth of stockOn the 14th of March, Ghanshyam Patel bought around 91k shares on-market at roughly ₹231 per share. This transaction amounted to 3.3% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth ₹36m. Ghanshyam has been a buyer over the last 12 months, purchasing a net total of ₹57m worth in shares.
Recent Insider Transactions • Jan 20CFO, MD & Director recently bought ₹36m worth of stockOn the 16th of January, Ghanshyam Patel bought around 120k shares on-market at roughly ₹301 per share. This transaction increased Ghanshyam's direct individual holding by 1x at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Ghanshyam's only on-market trade for the last 12 months.
Board Change • Dec 15Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Non-Executive Independent Director Chintan Bhatt was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.